Neogenomics Inc (NASDAQ: NEO) has reported a loss for its third fiscal quarter (ending September 30) of $-0.14 versus a loss $-0.15 for the same period a year ago — a decline of -7%. For the latest four quarters through September 30, E.P.S. were $-0.61 compared to $-0.77 a year ago — a decline of -21%.
Recent Price Action
Neogenomics Inc (NASDAQ: NEO) stock enjoyed a very large increase of 5.6% on 11/5/24. The shares closed at $14.93. Moreover, exceptionally high trading volume at 227% of normal accompanied the advance. The stock has performed in line with the market over the last nine months and has risen 10.8% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NEO is expected to continue to be Value Creation neutral.
Neogenomics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Neogenomics has a poor Appreciation Score of 29 but a slightly positive Power Rating of 64, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment